Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects

Next Previous
Trial Profile

Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 May 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SQ 109 (Primary) ; Moxifloxacin
  • Indications Crohn's disease; Duodenal ulcer; Helicobacter infections; Mycobacterial infections; Mycoses; Tuberculosis
  • Focus Adverse reactions

Most Recent Events

  • 20 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 13 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
  • 28 Jun 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top